Swiss drugmaker Roche raised its 2019 outlook after first-quarter sales rose 8 percent, beating analyst estimates on the strength of newer medicines including multiple sclerosis treatment Ocrevus and cancer immunotherapy Tecentriq.
from Reuters: Business News https://reut.rs/2KIXu1H
via IFTTT
from Reuters: Business News https://reut.rs/2KIXu1H
via IFTTT
إرسال تعليق